Companies › Price Vision Group
3 active drug programs in 4 registered trials: 4 Phase 2; Ophthalmology; next expected readout Jul 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Riboflavin 0.1% with UVA photoactivation (30 minute protocol) Riboflavin photosensitizer activated by UVA light to induce corneal crosslinking | – | Phase 2 | Corneal Neovascularization | Jul 2029 |
| Riboflavin 0.1% and non-pulsed light | – | Phase 2 | Keratoconus | Dec 2030 |
| Riboflavin 0.1% and pulsed light | – | Phase 2 | Keratoconus | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04787471 | Riboflavin 0.1% with UVA photoactivation (30 minute protocol) | Phase 2 | Corneal Neovascularization | Ophthalmology | Jul 2029 |
| NCT04787471 | Riboflavin 0.1% with UVA photoactivation (30 minute protocol) | Phase 2 | Corneal Neovascularization | Ophthalmology | Jul 2029 |
| NCT07841470 | Riboflavin 0.1% and pulsed light | Phase 2 | Keratoconus | Ophthalmology | Dec 2030 |
| NCT07841470 | Riboflavin 0.1% and non-pulsed light | Phase 2 | Keratoconus | Ophthalmology | Dec 2030 |
No annotated target.
–
NexThera Regenerative Patch Technologies jCyte NovaSight Emmecell
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.